J&J's anti-epileptic carisbamate submitted for US approval
This article was originally published in Scrip
Executive Summary
Johnson & JohnsonPharmaceutical Research and Development has submitted a US NDA for its potential anti-epileptic, carisbamate. The company has provisional approval from the FDA to market it as Comfyde.